GEN Exclusives

More »

GEN News Highlights

More »
May 10, 2013

Denovo Partners with ALS Nonprofit to ID Biomarkers

  • The ALS Emergency Treatment Fund (ALS-ETF) and Denovo Biomarkers are partnering in a pharmacogenomics-based effort to identify potential responder groups for drugs being studied in amyotrophic lateral sclerosis patients.

    Through this partnership, the firms will use Denovo technology to analyze samples obtained from expanded access programs that ALS-ETF sponsors with the hopes of identifying genomic biomarkers that correlate with treatment response, the firms said. Financial terms of the agreement were not disclosed.

    In a statement, Denovo CSO Wen Luo noted: "This partnership leverages the mission of ALS-ETF and the broad utility of our platform. We hope that our combined efforts will lead to better, more targeted treatments for ALS."


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should the CDC Director Resign?

Do you think the CDC chief should resign?